FDA authorizes new Phase 3 clinical trial of PrimeC for ALS

The U.S. Food and Drug Administration (FDA) has authorized Neurosense Therapeutics to begin a pivotal Phase 3 trial of its experimental oral therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The authorization follows the FDA’s positive feedback on the design of the PARAGON trial and…

The ALS Association is awarding $20,000 grants to 107 eligible clinics across the U.S. to help strengthen multidisciplinary care for people living with amyotrophic lateral sclerosis (ALS) and their families. The funding — totaling $2.14 million — comes from the Hugh and Herbert Hoffman ALS Impact Fund,…

My late husband, Jeff, grew up in a family of seven kids. The oldest and youngest were girls, with five boys in between. Jeff was right in the middle, which, he liked to explain with a laugh, made him the most well-adjusted. While all the kids were close, Jeff’s best…

We’ve been searching for a used car for our daughter, who’s in college. It’s been an interesting distraction for my husband, Todd, and me, because our days are often mundane. Our daughter is busy with classes, work, and dance, but because Todd has ALS and I am his caregiver,…

The ALS Network, in collaboration with ALS United, has announced the winners of the 2025 Research Innovation Grants, which support projects aimed at enhancing understanding and care for amyotrophic lateral sclerosis (ALS). This year’s group of 13 awarded research…

I’m looking forward to several events coming my way this holiday season. Not that my social calendar is filled up. Right now, I only have a few family get-togethers scheduled, all at restaurants with scrumptious buffets. (Yay!) I’ve learned, however, that holiday activities mixed with my ALS can add…

A bipartisan team of congressional representatives is pushing for new legislation that aims to understand why veterans are at increased risk of amyotrophic lateral sclerosis (ALS) and develop strategies to reduce this risk. The bill, dubbed the “Veterans with ALS Reporting Act,” was created in partnership with the…

Aperture Therapeutics has selected APRTX-001 as its lead candidate to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The therapy is designed to reduce the levels of CD33, a receptor protein on the surface of microglia — the resident immune cells of the central nervous system (CNS,…

In an upcoming episode of NBC’s TV show “Brilliant Minds,” actor Eric Dane will guest star as a character with amyotrophic lateral sclerosis (ALS), which he is also battling. ALS causes muscle weakness, which leads to other symptoms, such as trouble speaking, swallowing, and breathing. Though the…

M102, an experimental oral therapy designed to simultaneously activate two molecular pathways that protect against nerve cell damage, showed promise in preclinical models of amyotrophic lateral sclerosis (ALS), according to a study. The compound, discovered and developed by researchers at the University of Sheffield’s Institute for Translational Neuroscience (SITraN)…